New company to attempt another approach to utilize GDNF as PD treatment
Over the past two decades, biotech companies and clinicians have tried to develop a cure for Parkinson's disease based on Glial cell line-Derived Neurotrophic Factor (GDNF), a naturally occurring factor promoting the growth of dopamine neurons. Some clinical results were stunning, with patients experiencing a spectacular improvement in their symptoms and a return to 'normal' life. However, delivery of GDNF has been a major challenge. As it cannot be absorbed orally, a variety of delivery methods have been tested including direct pumping into the brain, intranasal delivery and gene therapy. Newly formed Mavalon Therapeutics is developing the first orally available small molecule able to induce GDNF production within the brain of Parkinson's patients, a treatment that will bring benefits to a larger population than the current intra-brain delivery of GDNF.
Domain Therapeutics and Medicxi partner to launch Mavalon Therapeutics This New Biotech wants to Regrow Neurons to cure Parkinson's |
Tupelo, do you know when phase 2 trials begin and will they conduct any trials in the states. Thanks for posting this. This is encouraging
|
It seems that a Phase II clinical trial is scheduled to start next year Medicxi founds Parkinson’s startup, commits €9M | FierceBiotech.
|
Quote:
|
All times are GMT -5. The time now is 02:49 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.